As noted earlier, the dual EGFR and Her2 inhibitor BIBW 2992 is currently being tested in a phase 2 and 3 clinical trial to explore efficacy in patients with lung adenocarcinoma harboring wildtype EGFR [38]. Here, EGFR is linked to lung adenocarcinoma.